MedTrace Logo

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

NCT03502746 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-05-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.

Conditions

  • Mesothelioma, Malignant

Interventions

DRUG

Nivolumab

Nivolumab 240mg, IV over 30 minutes.

DRUG

Ramucirumab

8mg/kg, IV over 60 minutes.

Sponsors & Collaborators

Principal Investigators

  • Arkadiusz Z Dudek, MD · HealthPartners Institute Regions Cancer Care Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-26
Primary Completion
2022-05-11
Completion
2023-11-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03502746 on ClinicalTrials.gov